Navigation Links
Discovery could help to develop drugs for organ transplant and cancer patients
Date:4/13/2012

MAYWOOD, Ill. -- Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others.

The finding eventually could lead to new drugs to regulate the immune system by, for example, revving it up to attack tumor cells or tamping it down to prevent the rejection of transplanted organs.

The study is published online ahead of print in the Journal of Immunology. Senior author is Makio Iwashima, PhD, an associate professor in the Department of Microbiology & Immunology of Loyola University Chicago Stritch School of Medicine. Co-authors are Robert Love, MD, a professor in the Departments of Thoracic & Cardiovascular Surgery and Microbiology & Immunology and one of the world's leading lung transplant surgeons, and first author Mariko Takami, PhD, of the Department of Microbiology & Immunology.

The immune system relies on a balancing act between two types of cells. Effector cells attack tumor cells and cells infected by viruses or bacteria. Regulatory cells suppress the immune system so that it does not attack healthy tissue. If effector cells are too active, an individual can suffer autoimmune disorders such as lupus, Type 1 diabetes and multiple sclerosis. But if regulatory cells are too active, the immune system will not be aggressive enough to protect the individual from germs and cancer.

The study involved an immune system molecule called transforming growth factor beta (TGF-β). TGF-β is known to be a powerful regulator of the immune response -- generally suppressing the strength of the response. In this study, however, Loyola researchers demonstrated that TGF-β can amplify the immune response and result in a more effective targeted response under specific conditions.

"TGF-β is a double-edged sword," Iwashima said. "It augments immune system reactions but does not determine what direction they will take. Depending on conditions, these reactions can either activate or suppress the immune system."

The study involved mouse cells grown ex vivo in laboratory dishes. The next steps will be to study TGF-β in human cells and in animal models. Understanding the dual role of TGF-β could help in the development of drugs to either activate or suppress the immune system, as needed, Iwashima said.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Washingtons Life Sciences Discovery Fund awards commercialization grants
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. New discovery of proteins involved in positioning muscular nuclei
4. Cell signaling discovery provides new hope for blood disorders
5. Gene mutation discovery sparks hope for effective endometriosis screening
6. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
7. Discovery of new vaccine approach for treatment of cancer
8. Zebrafish may help speed drug discovery
9. Unexpected discovery opens up new opportunities for targeting cancer
10. Journal names discovery that HIV treatment can prevent spread breakthrough of the year
11. Salk discovery may lead to safer treatments for asthma, allergies and arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Remote ... which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... remote participants for real-time collaboration and immediate decision-making requirements. While never sharing ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... **An FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... passing inspections and boosting quality. , It’s known as the “CY2016 Annual FDA ...
(Date:7/20/2017)... ... July 20, 2017 , ... With nearly half of all ... solution company VisitorsCoverage Inc. has launched TMQuotes, a new cloud-based solution platform which ... online, under their own brand. The online marketplace bridges the technological gap in ...
(Date:7/20/2017)... ... July 19, 2017 , ... At Creekwood Dental Arts, Drs. Donna G. ... treatment and dental implants in Waco, TX, using the latest dental technology ... by Tekscan®, they can capture details in the oral cavity for accurate diagnoses and ...
(Date:7/20/2017)... Washington (PRWEB) , ... July 19, 2017 , ... ... 11 “surprising habits” that may sometimes lead to, or worsen, varicose veins in ... Aesthetic Center notes that, while avoiding certain not-so-good practices, like excessive sitting or ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... to resolve pending patent litigation in the U.S. District Court ... regarding the Cialis ® (tadalafil) unit dose patent. This ... As part of the agreement, Cialis exclusivity is now expected ... "The unit dose patent for Cialis is valid and ...
(Date:7/11/2017)... 2017  Bayer has awarded grants totaling more than $2 ... its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians ... and Uniformed Services University of the Health Sciences ... Grant recipients were announced last night during a reception at ... Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
Breaking Medicine Technology: